EUVIMEDEUVIMED entdecken
Crossref

Nerandomilast, a PDE4B inhibitor, alleviates silica‐induced lung inflammation and fibrosis by inhibition of NLRP3 inflammasome and TGF‐β/Smad signalling

Yuanying Wang, Di Sun, Nafeisa Dilixiati, Dongmei Wang, Yawen Song, Qiao Ye iD

British Journal of Pharmacology · 2026-04 · 183 (7) · 1445-1464

DOI: 10.1111/bph.70240 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 19.11.2025. Verfasst von Yuanying Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Center for Interstitial Lung Diseases, Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Be…. Hauptthemen laut MEDLINE: Phosphodiesterase 4 Inhibitors, NLR Family, Pyrin Domain-Containing 3 Protein, Inflammasomes, Silicosis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Reform and Development Program of Beijing Institute of Respiratory Medicine, Beijing High-level Public Health Talent Construction Project, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Silicosis is a major cause of occupational disease‐related morbidity and mortality worldwide, yet effective pharmacological treatments remain limited. Nerandomilast, a novel inhibitor of phosphodiesterase‐4B (PDE4B), has demonstrated anti‐fibrotic potential in idiopathic pulmonary fibrosis (IPF); however, its efficacy and mechanisms in silicosis have not been investigated. Experimental Approach The therapeutic effects (and their underlying mechanisms) of PDE4B inhibition was evaluated in in models of silicosis, both in vivo (male C57BL/6N mice) and in vitro (THP‐1 macrophages and MRC‐5 cells). Single‐cell RNA sequencing, using lung tissue, was first performed to identify PDE4B as a key regulatory target in the pathogenesis of silicosis. Based on this finding, the therapeutic effects and underlying mechanisms of PDE4B inhibition were assessed using nerandomilast. Pulmonary function tests, inflammatory marker analyses and fibrosis evaluations were conducted to determine treatment efficacy. In addition, bulk RNA sequencing and transcriptomic analyses were performed to explore the molecular pathways modulated by nerandomilast. Key Results PDE4B inhibition effectively prevented and attenuated silica‐induced lung inflammation in the mouse model by suppressing both canonical and non‐canonical NLRP3 inflammasome pathways in lung macrophages. Furthermore, PDE4B inhibition down‐regulated TGF‐β/Smad signalling in lung fibroblasts of silicosis, leading to a significant reduction in fibrosis‐related gene expression. Conclusions and Implications These findings suggest that nerandomilast, a PDE4B inhibitor, may be a promising treatment for silicosis, which currently lacks effective therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphodiesterase 4 InhibitorsNLR Family, Pyrin Domain-Containing 3 ProteinInflammasomesSilicosisPneumoniaPulmonary FibrosisAnimalsMice, Inbred C57BLMaleSignal TransductionMiceTransforming Growth Factor betaSilicon DioxideHumansSmad ProteinsCyclic Nucleotide Phosphodiesterases, Type 4LungCell Line

Stichwörter der Autor:innen

NLRP3 inflammasomeTGF‐β/Smad signallingnerandomilastphosphodiesterase‐4B inhibitorsilicosis

Substanzen

Phosphodiesterase 4 InhibitorsNLR Family, Pyrin Domain-Containing 3 ProteinTransforming Growth Factor betaSilicon DioxideInflammasomesSmad ProteinsCyclic Nucleotide Phosphodiesterases, Type 4Nlrp3 protein, mouse

Autor:innen und Institutionen

  • Clinical Center for Interstitial Lung Diseases, Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
  • Department of Occupational Medicine and Toxicology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.

ORCID-Profile: Qiao Ye

Förderung

  • Reform and Development Program of Beijing Institute of Respiratory Medicine
  • Beijing High-level Public Health Talent Construction Project
  • National Natural Science Foundation of China

Zitieren

APA

Wang, Y., Sun, D., Dilixiati, N., Wang, D., Song, Y., & Ye, Q. (2026). Nerandomilast, a PDE4B inhibitor, alleviates silica‐induced lung inflammation and fibrosis by inhibition of NLRP3 inflammasome and TGF‐β/Smad signalling. British Journal of Pharmacology, 183(7), 1445-1464. https://doi.org/10.1111/bph.70240

Vancouver

Wang Y, Sun D, Dilixiati N, Wang D, Song Y, Ye Q. Nerandomilast, a PDE4B inhibitor, alleviates silica‐induced lung inflammation and fibrosis by inhibition of NLRP3 inflammasome and TGF‐β/Smad signalling. British Journal of Pharmacology. 2026;183(7):1445-1464. doi:10.1111/bph.70240

BibTeX
@article{Wang2026,
  author = {Wang, Yuanying and Sun, Di and Dilixiati, Nafeisa and Wang, Dongmei and Song, Yawen and Ye, Qiao},
  title = {Nerandomilast, a PDE4B inhibitor, alleviates silica‐induced lung inflammation and fibrosis by inhibition of NLRP3 inflammasome and TGF‐β/Smad signalling},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {7},
  pages = {1445--1464},
  doi = {10.1111/bph.70240}
}
Kostenlos starten →